Novonesis (novozymes) BNVZMF
13F holders, Q2 2025 (June 30)1holders
0new positions
0sold out
$71.45avg. 13F price*
At the end of Q2 2025, 1 institutions reported holding Novonesis (novozymes) B (NVZMF) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holder was Boston Common Asset Management, LLC ($1.2M).
- Company
- Novonesis (novozymes) B
- Filed as
- NOVOZYMES A/S (Q2 2025)
- CUSIP
- K7317J133
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 8,876 shares sold, net −8,876 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Boston Common Asset Management, LLC | 0.03% | Reduce -34.9% | 16,590 | $1.2M |
"% of holder's portfolio" is NVZMF's weight in each manager's 13F, not the share of Novonesis (novozymes) B the manager owns.